This implant can restore sight for patients with macular degeneration

Age-related macular degeneration, or AMD, is a common eye condition that affects more than 5 million people worldwide. It primarily impacts the macula, the central part of the retina responsible for sharp, detailed vision. In advanced stages, AMD causes a blind spot in the middle of a person’s vision, making activities like reading, recognizing faces, or using a phone difficult. The condition does not lead to complete blindness but significantly reduces the ability to see fine details. AMD develops as people age, and its exact cause remains unclear, though factors like genetics and lifestyle may play a role. Until recently, no treatment could restore vision lost to AMD, leaving many patients with limited options for managing their condition.

The Prima system is an innovative medical device designed to restore some vision for people with advanced AMD. Developed by Science Corporation, a company based in California, the system combines a retinal implant with a pair of camera-equipped eyeglasses. Unlike traditional treatments that focus on slowing the progression of AMD, Prima directly addresses vision loss by replacing the function of damaged cells in the retina. The retinal implant mimics the role of photoreceptors, which are the light-sensitive cells in the eye that convert light into electrical signals. These signals are then transmitted to healthy retinal cells, which process and send the information to the brain, allowing the user to perceive visual details again.

The Prima system consists of three main components: the glasses, a handheld processor, and the retinal implant. The glasses are equipped with a small, front-facing camera that captures real-time video of what the user is seeing. This video feed is transmitted via a fiber-optic cable to the handheld processor, which converts the video into infrared light signals. These signals are then sent back to the glasses, where a laser projector shines pulses of near-infrared light (at a wavelength of 880 nanometers) directly into the eye. The retinal implant, placed at the back of the eye, receives these light pulses and converts them into electrical signals using 378 tiny pixels, each containing an electrode and two photovoltaic cells.

Photovoltaic cells are a key feature of the Prima implant, serving two critical functions. First, they act like tiny solar panels, converting the incoming infrared light into electrical energy to power the implant, eliminating the need for an external battery. Second, they convert the light signals into electrical currents that stimulate the healthy bipolar and ganglion cells in the retina. These cells are part of the eye’s natural circuitry and normally transmit visual information to the brain. By bypassing the damaged photoreceptors, the implant allows the brain to receive visual information, restoring some degree of sight. This dual function of the photovoltaic cells ensures the implant is both self-sustaining and effective.

Clinical trials of the Prima system have shown promising results. After training sessions, more than 80% of recipients were able to perform tasks such as reading, doing crosswords, and using their phones, activities that were previously difficult or impossible due to AMD. The system was approved for use in Europe in July, marking a significant milestone for patients with advanced AMD. In the United States, the device is awaiting clearance from the FDA (Food and Drug Administration), which regulates medical devices and treatments. The approval process involves rigorous testing to ensure the device is safe and effective for public use. If approved, Prima could become a groundbreaking solution for millions of people affected by AMD worldwide.